Inclusion Pediatric and adult patients with suspected congenital primary and secondary erythrocytosis Patients < 20 years with polycythemia vera Exclusion.

Slides:



Advertisements
Similar presentations
MYELOPROLIFERATIVE DISEASES By DR. FATIMA AL-QAHTANI CONSULTANT HAEMATOLOGIST.
Advertisements

HEMATOLOGY WHAT IT IS : Study & measurement of individual elements of Blood. WHAT IT’S COMPOSED OF. SHOW SLIDES FROM PERIPHERAL BLOOD TUTOR CD OR USE PLATE.
An Approach to Anemia.
NEOPLASTIC DISORDERS OF THE BONE MARROW
Polycythemia Vera (lots of red cells - for real)
An approach to the patient with an abnormal CBC
Author(s): David Ginsburg, 2009 License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution–Noncommercial–Share.
WHO CLASSIFICATION OF MYELOID NEOPLASMS 2000  Chronic myeloproliferative disorders (CMPD)  Myelodysplastic / myeloproliferative diseases (MDS/MPD) 
APMG Pathologist, MD FCAP
Morning Report 7/7/2010 Pahresah Roomiany.  Factor V Leiden  Prothrombin gene mutation  Protein C/S deficiency  Antithrombin deficiency  Malignancy.
TYPES OF HEMOGLOBINS & HEMOGLOBINOPATHIES
Aswad H. Al.Obeidy FICMS, FICMS GE&Hep Kirkuk General Hospital
Myeloproliferative disorders Chris hatton. Proliferate or accumulative Bone marrow produces cells – mainly erythrocytes Bone marrow produces 10.
Chapter 7 Disorders of Blood Cells Lecture 7 The Nature of Disease Pathology for the Health Professions Thomas H. McConnell.
The Chronic Myeloproliferative Disorders
MLAB Hematology Keri Brophy-Martinez
Differential Diagnosis
MLAB Hematology Keri Brophy-Martinez Unit 23: CHRONIC MYELOPROLIFERATIVE DISORDERS (MPD)
Polycythemia Emmanuel Akuna Lab values. Normal platelet 150, ,000 CELLS/MM 3 Hemoglobin- men g/dl women g/dl Hematocrit.
Differential Diagnosis of Polycythemia Vera. True / Absolute Polycythemia Either a clonal myeloproliferative disorder (polycythemia vera) or a nonclonal.
THE PARADOXICAL RBC MEDICINE GRANDROUNDS December 2, 2010 Presented by: Suzanne V. Santos, M.D. Moderator: Jesus A. Relos, M.D., FPCP.
Lecture 2 Red Blood Cells, Anemias & Polycythemias
LABORATORIES de Guzman Raquel Isabelle & de Leon Gemma Rosa.
THROMBOTIC COMPLICATIONS IN PATIENTS WITH POLYCYTHEMIA VERA Coordinator: Asist. Univ. Dr. Marcela Candea Authors: Ioana-Violeta Oltean Ioana Barsan Madalina.
Myeloproliferative disorders Dr. Tariq Roshan PPSP Department of Hematology.
Myeloproliferative Disorders (MPD) concepts Neoplastic (clonal) disorders of hemopoietic stem cells Over-production of all cell lines, with usually one.
The Chronic Myeloproliferative Disorders (MPD) A JENABIAN MD.
Myeloproliferative disorders Clonal haematopoeitic disorders Proliferation of one of myeloid lineages –Granulocytic –Erythroid –Megakaryocytic Relatively.
Myeloproliferative Disorders (MPDs)
By Dr. Manal Basyouni Dr. Manal Basyouni. Heme consists of a Porphyrin ring coordinated with iron. It is found mainly in hemoglobin but also present in.
Red blood Cell Changes and Circulatory problems
Hypercoagulable States: Polycythemia Vera Chris Caulfield AM Report Oct 20, 2009.
About these slides SPEC – Short Presentation in Emerging Concepts
MYELOPROLIFERATIVE DISORDERS EVOLVING CONCEPTS
Definition of polycythemia
Myeloproliferative Diseases Mark D. Browning, M.D. Oncology/Hematology Associates February 24, 2016.
Gary Schiller, MD Nothing to disclose Discussion of off-label drug use: not applicable 56 th ASH Annual Meeting Disclosure Statement.
Biochemical and genetic evaluation in amyloidosis
October 2014 Myeloproliferative Neoplasms Angela Fleischman Division of hematology/Oncology.
골수증식 질환 Myeloproliferative disorders (MPD) [ 새로운 분류와 진단 기준 ] 경희의대 종양혈액내과 조 경 삼.
Definition of polycythemia
Department of Hematology and Oncology R3 Joonbeom Shin
Hematocrit.
Pediatric polycytemia case presentation
The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases Jean-Jacques Kiladjian et. al Blood.
Characterization of VHL promoter variants in patients suspected of Von Hippel Lindau Saleh Albanyan, Rachel Giles, Raymond H Kim, MD/PhD Division of.
Definition of polycythemia
MYELOPROLIFERATIVE DISORDERS
Polycythemia Vera Bleeding Disorders
Mastocytosis Molecular
POLYCYTHEMIA VERA.
RBC disorders 5 Ahmad Mansour, MD.
Assistant Prof. Dr. Nibras Saleam Al-Ammar PhD in Clinical Immunology
Do you have any suggestions? Please contact us!
Erythropoietin (EPO) measurements in patients with various forms of erythrocytosis. When compared with the normal response, polycythemia vera patients.
Chronic Myeloproliferative Neoplasms (MPN) Ph-negative
Red Blood Cell Disorders
Diagnosing Polycythemia Vera: A Paradigm Shift
Polycythemia Vera: A Comprehensive Review and Clinical Recommendations
Prefibrotisk Myelofibros
Erythropoietin (EPO) Mike Lin.
Leukemia case Maha Areej Faten.
Male patient of 52 years old with a two-year history of fatigue and pruritus of his legs , headache . And visual disturbances . He smoked one pack of.
Pathogenesis of myeloproliferative neoplasms
In the name of God Zahra Barzang
Detection of the Activating JAK2 V617F Mutation in Paraffin-Embedded Trephine Bone Marrow Biopsies of Patients with Chronic Myeloproliferative Diseases 
Ayalew Tefferi, Pierre Noel, Curtis A. Hanson 
Sanger sequencing results
Rene L. Begay et al. BTS 2016;1: Affected Individuals Carry a Mutation at the Intronic Border of Exon 43 (A) Sanger sequenced chromatogram of healthy.
The Non – Leukemic Myeloproliferative Disorders
Presentation transcript:

Inclusion Pediatric and adult patients with suspected congenital primary and secondary erythrocytosis Patients < 20 years with polycythemia vera Exclusion Patients with secondary erythrocytosis due to a known cardiac, pulmonary, or renal disease Observational patients Patients with secondary erythrocytosis due to an underlying disorder (e.g. renal disorder, Epo- producing tumor) which has been identified during the diagnostic work-up of apparent idiopathic erythrocytosis

Before the inclusion of a patient with suspected congenital erythrocytosis or PV in childhood and adolescence into the register exclude causes for relative or apparent erythrocytosis (e.g. dehydration, Smoker‘s polycythemia) confirm the presence of absolute erythrocytosis in an independent analysis exclude obvious cardiac and pulmonary causes of secondary erythrocytoses (e.g. COPD, cyanotic cardiac defects) in patients older than 20 years, exclude polycythemia vera according to established diagnostic criteria (PVSG and/or WHO)

Serum erythropoietin  (or upper normal range) Serum erythropoietin  (or lower normal range) PRV-1mRNA expression nl.; ØEEC ; JAK2 V617F - PRV-1mRNA expression  ; EEC  ; JAK2 V617F + Polycythemia vera  BM biopsy & cytogenetics Sequencing of EPOR gene exon 7+8  Epo sensitivity assay “+”  PFCP “-”  PFCP ?   BM biopsy Hemoglobin oxygen affinity nl.Hemoglobin oxygen affinity  VHL gene analysis Hemoglobin analysis nlAbnormal hemoglobin Globin gene analysis Chuvash P./other VHL mutation? further endocrinol. & nephrol. diagnostics (e.g. angiography) Exclusion of Epo-producing tumour ( CNS-MRI, sonography) 2,3-BPG quantification 2,3-BPG deficiency ? 2,3-BPG mutase  ? Hereditary PK abnormality ? hemoglobin variant with hyperaffinity to O 2 Diagnostic algorithm for absolute erythrocytoses PHD2 gene analysis (& other g.) Red cell mass  (> mean + 25%) or hemoglobin or hematocrit  (> mean + 2 SD) SaO 2 >92 %SaO 2 <92 %Cardiac or pulmonary disorder?  leukocytosis  thrombocytosis  splenomegaly Polycythemia vera ?  PRV-1, EEC, JAK2, BM Isolated erythrocytosis, no significant splenomegaly

Serum erythropoietin  (or upper normal range) Serum erythropoietin  (or lower normal range) PRV-1mRNA expression nl.; ØEEC ; JAK2 V617F - PRV-1mRNA expression  ; EEC  ; JAK2 V617F + Polycythemia vera  BM biopsy & cytogenetics Sequencing of EPOR gene exon 7+8  Epo sensitivity assay “+”  PFCP “-”  PFCP ?   BM biopsy Hemoglobin oxygen affinity nl.Hemoglobin oxygen affinity  VHL gene analysis Hemoglobin analysis nlAbnormal hemoglobin Globin gene analysis Chuvash P./other VHL mutation? further endocrinol. & nephrol. diagnostics (e.g. angiography) Exclusion of Epo-producing tumour ( CNS-MRI, sonography) 2,3-BPG quantification 2,3-BPG deficiency ? 2,3-BPG mutase  ? Hereditary PK abnormality ? hemoglobin variant with hyperaffinity to O 2 Diagnostic algorithm for absolute erythrocytoses PHD2 gene analysis (& other g.) Red cell mass  (> mean + 25%) or hemoglobin or hematocrit  (> mean + 2 SD) SaO 2 >92 %SaO 2 <92 %Cardiac or pulmonary disorder?  leukocytosis  thrombocytosis  splenomegaly Polycythemia vera ?  PRV-1, EEC, JAK2, BM Isolated erythrocytosis, no significant splenomegaly

Serum erythropoietin  (or upper normal range) Serum erythropoietin  (or lower normal range) PRV-1mRNA expression nl.; ØEEC ; JAK2 V617F - PRV-1mRNA expression  ; EEC  ; JAK2 V617F + Polycythemia vera  BM biopsy & cytogenetics Sequencing of EPOR gene exon 7+8  Epo sensitivity assay “+”  PFCP “-”  PFCP ?   BM biopsy Hemoglobin oxygen affinity nl.Hemoglobin oxygen affinity  VHL gene analysis Hemoglobin analysis nlAbnormal hemoglobin Globin gene analysis Chuvash P./other VHL mutation? further endocrinol. & nephrol. diagnostics (e.g. angiography) Exclusion of Epo-producing tumour ( CNS-MRI, sonography) 2,3-BPG quantification 2,3-BPG deficiency ? 2,3-BPG mutase  ? Hereditary PK abnormality ? hemoglobin variant with hyperaffinity to O 2 Diagnostic algorithm for absolute erythrocytoses PHD2 gene analysis (& other g.) Red cell mass  (> mean + 25%) or hemoglobin or hematocrit  (> mean + 2 SD) SaO 2 >92 %SaO 2 <92 %Cardiac or pulmonary disorder?  leukocytosis  thrombocytosis  splenomegaly Polycythemia vera ?  PRV-1, EEC, JAK2, BM Isolated erythrocytosis, no significant splenomegaly

Serum erythropoietin  (or upper normal range) Serum erythropoietin  (or lower normal range) PRV-1mRNA expression nl.; ØEEC ; JAK2 V617F - PRV-1mRNA expression  ; EEC  ; JAK2 V617F + Polycythemia vera  BM biopsy & cytogenetics Sequencing of EPOR gene exon 7+8  Epo sensitivity assay “+”  PFCP “-”  PFCP ?   BM biopsy Hemoglobin oxygen affinity nl.Hemoglobin oxygen affinity  VHL gene analysis Hemoglobin analysis nlAbnormal hemoglobin Globin gene analysis Chuvash P./other VHL mutation? further endocrinol. & nephrol. diagnostics (e.g. angiography) Exclusion of Epo-producing tumour ( CNS-MRI, sonography) 2,3-BPG quantification 2,3-BPG deficiency ? 2,3-BPG mutase  ? Hereditary PK abnormality ? hemoglobin variant with hyperaffinity to O 2 Diagnostic algorithm for absolute erythrocytoses PHD2 gene analysis (& other g.) Red cell mass  (> mean + 25%) or hemoglobin or hematocrit  (> mean + 2 SD) SaO 2 >92 %SaO 2 <92 %Cardiac or pulmonary disorder?  leukocytosis  thrombocytosis  splenomegaly Polycythemia vera ?  PRV-1, EEC, JAK2, BM Isolated erythrocytosis, no significant splenomegaly

Serum erythropoietin  (or upper normal range) Serum erythropoietin  (or lower normal range) PRV-1mRNA expression nl.; ØEEC ; JAK2 V617F - PRV-1mRNA expression  ; EEC  ; JAK2 V617F + Polycythemia vera  BM biopsy & cytogenetics Sequencing of EPOR gene exon 7+8  Epo sensitivity assay “+”  PFCP “-”  PFCP ?   BM biopsy Hemoglobin oxygen affinity nl.Hemoglobin oxygen affinity  VHL gene analysis Hemoglobin analysis nlAbnormal hemoglobin Globin gene analysis Chuvash P./other VHL mutation? further endocrinol. & nephrol. diagnostics (e.g. angiography) Exclusion of Epo-producing tumour ( CNS-MRI, sonography) 2,3-BPG quantification 2,3-BPG deficiency ? 2,3-BPG mutase  ? Hereditary PK abnormality ? hemoglobin variant with hyperaffinity to O 2 Diagnostic algorithm for absolute erythrocytoses PHD2 gene analysis (& other g.) Red cell mass  (> mean + 25%) or hemoglobin or hematocrit  (> mean + 2 SD) SaO 2 >92 %SaO 2 <92 %Cardiac or pulmonary disorder?  leukocytosis  thrombocytosis  splenomegaly Polycythemia vera ?  PRV-1, EEC, JAK2, BM Isolated erythrocytosis, no significant splenomegaly

Serum erythropoietin  (or upper normal range) Serum erythropoietin  (or lower normal range) PRV-1mRNA expression nl.; ØEEC ; JAK2 V617F - PRV-1mRNA expression  ; EEC  ; JAK2 V617F + Polycythemia vera  BM biopsy & cytogenetics Sequencing of EPOR gene exon 7+8  Epo sensitivity assay “+”  PFCP “-”  PFCP ?   BM biopsy Hemoglobin oxygen affinity nl.Hemoglobin oxygen affinity  VHL gene analysis Hemoglobin analysis nlAbnormal hemoglobin Globin gene analysis Chuvash P./other VHL mutation? further endocrinol. & nephrol. diagnostics (e.g. angiography) Exclusion of Epo-producing tumour ( CNS-MRI, sonography) 2,3-BPG quantification 2,3-BPG deficiency ? 2,3-BPG mutase  ? Hereditary PK abnormality ? hemoglobin variant with hyperaffinity to O 2 Diagnostic algorithm for absolute erythrocytoses PHD2 gene analysis (& other g.) Red cell mass  (> mean + 25%) or hemoglobin or hematocrit  (> mean + 2 SD) SaO 2 >92 %SaO 2 <92 %Cardiac or pulmonary disorder?  leukocytosis  thrombocytosis  splenomegaly Polycythemia vera ?  PRV-1, EEC, JAK2, BM Isolated erythrocytosis, no significant splenomegaly

Serum erythropoietin  (or upper normal range) Serum erythropoietin  (or lower normal range) PRV-1mRNA expression nl.; ØEEC ; JAK2 V617F - PRV-1mRNA expression  ; EEC  ; JAK2 V617F + Polycythemia vera  BM biopsy & cytogenetics Sequencing of EPOR gene exon 7+8  Epo sensitivity assay “+”  PFCP “-”  PFCP ?   BM biopsy Hemoglobin oxygen affinity nl.Hemoglobin oxygen affinity  VHL gene analysis Hemoglobin analysis nlAbnormal hemoglobin Globin gene analysis Chuvash P./other VHL mutation? further endocrinol. & nephrol. diagnostics (e.g. angiography) Exclusion of Epo-producing tumour ( CNS-MRI, sonography) 2,3-BPG quantification 2,3-BPG deficiency ? 2,3-BPG mutase  ? Hereditary PK abnormality ? hemoglobin variant with hyperaffinity to O 2 Diagnostic algorithm for absolute erythrocytoses PHD2 gene analysis (& other g.) Red cell mass  (> mean + 25%) or hemoglobin or hematocrit  (> mean + 2 SD) SaO 2 >92 %SaO 2 <92 %Cardiac or pulmonary disorder?  leukocytosis  thrombocytosis  splenomegaly Polycythemia vera ?  PRV-1, EEC, JAK2, BM Isolated erythrocytosis, no significant splenomegaly

Serum erythropoietin  (or upper normal range) Serum erythropoietin  (or lower normal range) PRV-1mRNA expression nl.; ØEEC ; JAK2 V617F - PRV-1mRNA expression  ; EEC  ; JAK2 V617F + Polycythemia vera  BM biopsy & cytogenetics Sequencing of EPOR gene exon 7+8  Epo sensitivity assay “+”  PFCP “-”  PFCP ?   BM biopsy Hemoglobin oxygen affinity nl.Hemoglobin oxygen affinity  VHL gene analysis Hemoglobin analysis nlAbnormal hemoglobin Globin gene analysis Chuvash P./other VHL mutation? further endocrinol. & nephrol. diagnostics (e.g. angiography) Exclusion of Epo-producing tumour ( CNS-MRI, sonography) 2,3-BPG quantification 2,3-BPG deficiency ? 2,3-BPG mutase  ? Hereditary PK abnormality ? hemoglobin variant with hyperaffinity to O 2 Diagnostic algorithm for absolute erythrocytoses PHD2 gene analysis (& other g.) Red cell mass  (> mean + 25%) or hemoglobin or hematocrit  (> mean + 2 SD) SaO 2 >92 %SaO 2 <92 %Cardiac or pulmonary disorder?  leukocytosis  thrombocytosis  splenomegaly Polycythemia vera ?  PRV-1, EEC, JAK2, BM Isolated erythrocytosis, no significant splenomegaly

Serum erythropoietin  (or upper normal range) Serum erythropoietin  (or lower normal range) PRV-1mRNA expression nl.; ØEEC ; JAK2 V617F - PRV-1mRNA expression  ; EEC  ; JAK2 V617F + Polycythemia vera  BM biopsy & cytogenetics Sequencing of EPOR gene exon 7+8  Epo sensitivity assay “+”  PFCP “-”  PFCP ?   BM biopsy Hemoglobin oxygen affinity nl.Hemoglobin oxygen affinity  VHL gene analysis Hemoglobin analysis nlAbnormal hemoglobin Globin gene analysis Chuvash P./other VHL mutation? further endocrinol. & nephrol. diagnostics (e.g. angiography) Exclusion of Epo-producing tumour ( CNS-MRI, sonography) 2,3-BPG quantification 2,3-BPG deficiency ? 2,3-BPG mutase  ? Hereditary PK abnormality ? hemoglobin variant with hyperaffinity to O 2 Diagnostic algorithm for absolute erythrocytoses PHD2 gene analysis (& other g.) Red cell mass  (> mean + 25%) or hemoglobin or hematocrit  (> mean + 2 SD) SaO 2 >92 %SaO 2 <92 %Cardiac or pulmonary disorder?  leukocytosis  thrombocytosis  splenomegaly Polycythemia vera ?  PRV-1, EEC, JAK2, BM Isolated erythrocytosis, no significant splenomegaly

Serum erythropoietin  (or upper normal range) Serum erythropoietin  (or lower normal range) PRV-1mRNA expression nl.; ØEEC ; JAK2 V617F - PRV-1mRNA expression  ; EEC  ; JAK2 V617F + Polycythemia vera  BM biopsy & cytogenetics Sequencing of EPOR gene exon 7+8  Epo sensitivity assay “+”  PFCP “-”  PFCP ?   BM biopsy Hemoglobin oxygen affinity nl.Hemoglobin oxygen affinity  VHL gene analysis Hemoglobin analysis nlAbnormal hemoglobin Globin gene analysis Chuvash P./other VHL mutation? further endocrinol. & nephrol. diagnostics (e.g. angiography) Exclusion of Epo-producing tumour ( CNS-MRI, sonography) 2,3-BPG quantification 2,3-BPG deficiency ? 2,3-BPG mutase  ? Hereditary PK abnormality ? hemoglobin variant with hyperaffinity to O 2 Diagnostic algorithm for absolute erythrocytoses PHD2 gene analysis (& other g.) Red cell mass  (> mean + 25%) or hemoglobin or hematocrit  (> mean + 2 SD) SaO 2 >92 %SaO 2 <92 %Cardiac or pulmonary disorder?  leukocytosis  thrombocytosis  splenomegaly Polycythemia vera ?  PRV-1, EEC, JAK2, BM Isolated erythrocytosis, no significant splenomegaly